Category: Merck KGaA

Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer

June 24, 2009 by srrpenna

Oncothyreon Inc. announced that Merck KGaA has initiated a global Phase 3 trial of Stimuvax(R) (BLP25 liposome vaccine, L-BLP25) in patients with hormone receptor-positive, locally advanced, recurrent or metastatic breast cancer. The Phase 3 trial, named STRIDE (STimulating immune Response In aDvanced brEast cancer), is anticipated to enroll more than 900 patients at approximately 180 sites in over 30 countries - including North America, Europe, Asia and Australia.